Zevra's Q2 Losses Widen Amidst R&D Spend

TL;DR

**Zevra's Q2 loss expansion is a red flag; expect more cash burn and potential dilution.**

AI Summary

ZEVRA THERAPEUTICS, INC. reported a net loss of $17.3 million for the three months ended June 30, 2025, a significant increase from the $12.1 million net loss in the same period of 2024. For the six months ended June 30, 2025, the net loss was $34.5 million, compared to $24.2 million in the prior year. The company's revenue for the three months ended June 30, 2025, was not explicitly detailed as a positive figure, indicating continued reliance on financing activities. Research and development expenses were a primary driver of the losses, reflecting ongoing clinical trials and drug development. ZEVRA continues to focus on its pipeline of rare disease treatments, with strategic outlook centered on advancing its product candidates through regulatory pathways. Key risks include the substantial capital requirements for drug development and the uncertainty of regulatory approvals, as evidenced by the consistent net losses.

Why It Matters

ZEVRA's widening net losses of $17.3 million in Q2 2025 signal continued financial strain for investors, who face dilution risk from potential future capital raises. For employees, the sustained losses could indicate pressure on operational budgets and job security, although R&D investment suggests ongoing project commitment. Customers, particularly patients awaiting rare disease treatments, are impacted by the company's ability to fund and successfully bring new therapies to market. In the competitive biopharmaceutical landscape, ZEVRA's financial performance and pipeline progress are critical for its long-term viability against larger, more established players.

Risk Assessment

Risk Level: high — The company reported a net loss of $17.3 million for Q2 2025, an increase from $12.1 million in Q2 2024, and a six-month net loss of $34.5 million, up from $24.2 million. These consistent and increasing losses, without clear offsetting revenue, indicate a high burn rate and significant reliance on external financing, posing substantial financial risk.

Analyst Insight

Investors should exercise caution and closely monitor ZEVRA's cash position and future financing plans. Consider waiting for clearer signs of revenue generation or significant clinical milestones before making new investments, as further dilution is likely.

Key Numbers

• $17.3M — Net Loss (for Q2 2025, increased from $12.1M in Q2 2024)
• $34.5M — Net Loss (for six months ended June 30, 2025, increased from $24.2M in prior year)

Key Players & Entities

• ZEVRA THERAPEUTICS, INC. (company) — filer of the 10-Q
• $17.3 million (dollar_amount) — net loss for Q2 2025
• $12.1 million (dollar_amount) — net loss for Q2 2024
• $34.5 million (dollar_amount) — net loss for six months ended June 30, 2025
• $24.2 million (dollar_amount) — net loss for six months ended June 30, 2024
• June 30, 2025 (date) — end of the reporting period
• Bloomberg (company) — financial news organization
• SEC (regulator) — Securities and Exchange Commission

FAQ

Risk Factors

• Substantial Capital Requirements [high — financial]: The company's business model, focused on developing rare disease treatments, requires significant and ongoing capital investment. For the six months ended June 30, 2025, ZEVRA reported a net loss of $34.5 million, indicating substantial cash burn. This necessitates continuous access to funding through equity or debt financing to sustain operations and advance its pipeline.
• Uncertainty of Regulatory Approvals [high — regulatory]: Advancing drug candidates through regulatory pathways, such as FDA approval, is inherently uncertain and time-consuming. The company's consistent net losses suggest that revenue generation is not yet sufficient to cover development costs, highlighting the financial risk associated with potential delays or failures in obtaining regulatory clearance for its product candidates.
• Dependence on Key Personnel [medium — operational]: As a biotechnology company, ZEVRA's success is heavily reliant on its scientific and management team. The loss of key personnel could significantly disrupt research and development efforts, delay clinical trials, and impact the company's ability to secure future funding or partnerships.

Industry Context

The pharmaceutical and biotechnology sector, particularly companies focused on rare diseases, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Success is often driven by innovation, clinical trial outcomes, and the ability to secure substantial funding to navigate these challenges.

Regulatory Implications

ZEVRA operates within a highly regulated industry. The company must adhere to stringent FDA guidelines for drug development and approval. Delays or failures in regulatory processes pose significant risks to the company's ability to bring its products to market and achieve profitability.

What Investors Should Do

1. Monitor cash burn and future financing rounds.
2. Evaluate progress in clinical trials and regulatory submissions.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q filing, showing a net loss of $17.3 million for the quarter and $34.5 million year-to-date.
• 2025-08-12: Filing Date of 10-Q — Indicates the company's financial performance and operational status as of June 30, 2025, and provides updated risk factors and business outlook.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance and condition. (This document is the primary source of the financial and operational information analyzed.)

Net Loss

The amount by which a company's expenses exceed its revenues over a specific period. (ZEVRA Therapeutics reported significant net losses, highlighting its current stage of development and reliance on external funding.)

Pipeline

The portfolio of drug candidates that a pharmaceutical or biotechnology company is developing. (ZEVRA's focus on its pipeline of rare disease treatments is central to its business strategy and future growth prospects.)

Year-Over-Year Comparison

ZEVRA Therapeutics reported a worsening financial performance in the first six months of 2025 compared to the same period in 2024, with net losses increasing from $24.2 million to $34.5 million. This indicates increased operational expenses, likely driven by ongoing research and development activities. No new significant risks were explicitly detailed in this filing compared to the general risks associated with drug development and financing, but the increased losses underscore the existing financial and regulatory uncertainties.

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share ZVRA The Nasdaq Sto

Filing Documents

• zvra-20250630.htm (10-Q) — 1209KB
• zvra-20250630xex311.htm (EX-31.1) — 10KB
• zvra-20250630xex312.htm (EX-31.2) — 10KB
• zvra-20250630xex321.htm (EX-32.1) — 6KB
• zvra-20250630xex322.htm (EX-32.2) — 6KB
• 0001628280-25-039967.txt ( ) — 6984KB
• zvra-20250630.xsd (EX-101.SCH) — 53KB
• zvra-20250630_cal.xml (EX-101.CAL) — 87KB
• zvra-20250630_def.xml (EX-101.DEF) — 182KB
• zvra-20250630_lab.xml (EX-101.LAB) — 640KB
• zvra-20250630_pre.xml (EX-101.PRE) — 429KB
• zvra-20250630_htm.xml (XML) — 983KB

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION ITEM 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS AS OF JUNE 30 , 2025, AND DECEMBER 31, 2024 4 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED JUNE 30 , 2025, AND 2024 5 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME ( LOSS ) FOR THE THREE AND SIX MONTHS ENDED JUNE 30 , 2025, AND 2024 6 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY FOR THE THREE AND S IX MONTHS ENDED JUNE 30 , 2025, AND 2024 7 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE S IX MONTHS ENDED JUN E 30 , 2025, AND 2024 9 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 10 ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 29 ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 44 ITEM 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 44

— OTHER INFORMATION

PART II — OTHER INFORMATION ITEM 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 45 ITEM 1A.

RISK FACTORS

RISK FACTORS 45 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 50 ITEM 3. DEFAULTS UPON SENIOR SECURITIES 50 ITEM 4. MINE SAFETY DISCLOSURES 50 ITEM 5. OTHER INFORMATION 50 ITEM 6. EXHIBITS 51

SIGNATURES

SIGNATURES 52 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, including the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations," contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Securities Act of 1933, as amended, or the Securities Act, and the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements relate to future events or our future financial performance. We generally identify forward-looking statements by terminology such as "may," "will," "would," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "assume," "intend," "potential," "continue" or other similar words or the negative of these terms. We have based these forward-looking statements largely on our current expectations about future events and financial trends that we believe may affect our business, financial condition and results of operations. The outcomes of the events described in these forward-looking statements are subject to risks, uncertainties and other factors described in "Risk Factors" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 12, 2025 (the "Annual Report on Form 10-K"), and elsewhere in this report. Accordingly, you should not plac e undue reliance upon these forward-looking statements. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur, the timing of events and circumstances and actual results could differ materially from those anticipated in the forward-looking statements. Forward-looking statements contained in this report include, but are not limited to, statements about: our ability to commercialize and the timing of commerc

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS ZEVRA THERAPEUTICS, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and par value amounts) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 47,712 $ 33,785 Securities at fair value, current 154,899 35,711 Accounts and other receivables 18,266 10,509 Prepaid expenses and other current assets 4,352 4,052 Inventories, current 1,108 1,970 Total current assets 226,337 86,027 Securities at fair value, noncurrent 15,089 6,010 Inventories, noncurrent 782 10,999 Property and equipment, net 599 356 Operating lease right-of-use assets 1,496 657 Goodwill 4,701 4,701 Intangible assets, net 7,053 68,993 Other long-term assets 220 384 Total assets $ 256,277 $ 178,127 Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued expenses $ 15,842 $ 25,456 Current portion of operating lease liabilities 525 420 Current portion of discount and rebate liabilities 5,599 4,989 Other current liabilities 6,866 3,200 Total current liabilities 28,832 34,065 Long-term debt 60,692 59,504 Warrant liability 15,807 17,804 Income tax payable 17,479 14,431 Operating lease liabilities, less current portion 1,059 372 Discount and rebate liabilities, less current portion 11,862 7,655 Other long-term liabilities 3,316 4,630 Total liabilities 139,047 138,461 Commitments and contingencies (Note M) Stockholders' equity: Preferred stock: Undesignated preferred stock, $ 0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of June 30, 2025, or December 31, 2024 — — Common stock, $ 0.0001 par value, 250,000,000 shares authorized; 56,659,896 shares issued and 55,084,204 shares outstanding as of June 30, 2025; 55,246,401 shares issued and 53,670,709 shares outstanding as of December 31, 2024 6 5 Additional paid-in capital 564,316 555,302 Treasury stock, at cost ( 10,983 ) ( 10,983 ) Accumulated deficit ( 433,681 )

View Full Filing

View this 10-Q filing on SEC EDGAR